Auris Medical AG Announces Enrollment Of First Patient In North American Phase 3 Study Of AM-101 In Treatment Of Acute Peripheral Tinnitus
3/10/2014 9:12:37 AM
BASEL, Switzerland, March 10, 2014 (GLOBE NEWSWIRE) -- Auris Medical today announced enrollment of the first patient into the TACTT21 clinical trial. This phase 3 trial will evaluate the efficacy, safety and tolerability of intratympanic injections of AM-101 in the treatment of acute peripheral tinnitus following traumatic cochlear injury or otitis media. TACTT2 will enroll 330 patients at more than 60 sites primarily in the United States and Canada.
Help employers find you! Check out all the jobs and post your resume.
comments powered by